Shares of Insilico Medicine (03696) rose nearly 11% in morning trading. At the time of writing, the stock was up 10.86% to HK$51.35, with a turnover of HK$516 million.

The company announced it has entered into a strategic collaboration alliance with Bora Pharmaceuticals Co., Ltd.. This alliance will be established on a broad, multi-faceted cooperative framework. The specific collaboration details will be further discussed and finalized in a definitive agreement to be signed by both parties. If fully implemented, the potential total value of this partnership could exceed US$2.5 billion.

It is understood that the proposed cooperation under this alliance will be defined through subsequent negotiations and the signing of a final agreement between Insilico Medicine and Bora. It aims to integrate the technological strengths of Insilico Medicine's proprietary Pharma.AI platform in areas such as target discovery, generative chemistry, and molecular optimization, with Bora's professional capabilities in global drug development, manufacturing, quality management, and commercialization. By connecting an AI-empowered R&D system with an automation-driven development, manufacturing, and quality execution process, Insilico Medicine and Bora aim to jointly pioneer a new generation of drug innovation models, bridging the capabilities required from the design and development of novel molecules to their manufacturing and delivery to patients with unmet medical needs.